Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
pharmaphorum18h
bluebird claims first approval for gene therapy Zynteglo in EU
bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia. The EU regulator has ...